Pharmadule strengthens its presence in China

Pharmadule, a global supplier of high-tech modular facilities for the pharmaceutical and biopharmaceutical industries headquartered in Stockholm, Sweden, has established access to local production in China through a partnership with Morimatsu Group.

Pharmadule, a global supplier of high-tech modular facilities for the pharmaceutical and biopharmaceutical industries headquartered in Stockholm, Sweden, has established access to local production in China through a partnership with Morimatsu Group.

The agreement will give Morimatsu manufacturing rights to modules with Pharmadule for the Chinese market. The cooperation supplements Pharmadule's main production facility in Tallinn, Estonia.

"To serve the rapidly growing market in China, local presence is essential," said Lars Martinsson, ceo of Pharmadule. "We see a trend among our customers to expand in that area and Morimatsu provides an excellent opportunity for us. Our customers will now benefit by being able to use Pharmadule's modular concept locally for investments in China."

Japanese firm Morimatsu has expertise in providing tanks and equipment for the pharmaceuticals industry and has been serving the Chinese market for 20 years. It has a factory in Shanghai, one of the pharmaceutical manufacturing clusters in China, which will enable production to start immediately.

Since 1986 Pharmadule has supplied 60 manufacturing facilities to the pharmaceutical and biopharmaceutical industries worldwide including to Eli Lilly, Merck, Baxter, GlaxoSmithKline, Genentech, Pharmacia and AstraZeneca.




Companies